文献速递临床试验与 GCP基础与转化研究

槲寄生提取物辅助标准治疗晚期胰腺癌的随机双盲安慰剂对照试验方案

Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL).
PubMed 文献 · Trials · 2020-09-11

本研究为多中心、平行组、双盲、随机、安慰剂对照临床试验,计划纳入290例晚期胰腺癌患者,评估槲寄生提取物辅助标准治疗(姑息化疗或最佳支持治疗)对总生存期和健康相关生活质量的影响。槲寄生提取物皮下注射剂量从0.01mg递增至20mg,每周三次,持续9个月。

要点

  • 首个安慰剂对照随机试验评估槲寄生提取物辅助治疗晚期胰腺癌的疗效。
  • 主要结局为总生存期和健康相关生活质量。
  • 槲寄生提取物皮下注射剂量从0.01mg递增至20mg,每周三次,持续9个月。

核心结论

  • 该试验旨在评估槲寄生提取物作为标准治疗辅助手段对晚期胰腺癌患者总生存期和健康相关生活质量的價值。

研究设计与样本

  • 前瞻性、随机、双盲、多中心、平行组、安慰剂对照临床试验,计划纳入290例晚期胰腺癌患者。
  • 参与者随机分配至安慰剂组或槲寄生提取物组,按中心和姑息化疗进行分层。

关键数值与推荐

  • 槲寄生提取物皮下注射剂量从0.01mg递增至20mg,每周三次,持续9个月。
  • 主要纳入标准为晚期胰腺癌且ECOG体能状态评分0至2;主要排除标准为预期寿命小于4周和胰腺神经内分泌肿瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most pancreatic cancer patients present with advanced stage at diagnosis with extremely short expected survival and few treatment options. A multimodal palliative approach is necessary for symptom relief and optimisation of health-related quality of life. In a recent open-label trial of mistletoe extract for advanced pancreatic cancer patients not eligible for chemotherapy, promising results on improved overall survival and better health-related quality of life were reported. The objective of the present study is to assess the value of mistletoe extract as a complement to standard treatment (palliative chemotherapy or best supportive care) in advanced pancreatic cancer patients with regard to overall survival and health-related quality of life. METHODS: The trial is prospective, randomised, double-blind, multicentre, parallel group and placebo-controlled. In total, 290 participants are randomly assigned to placebo or mistletoe extract given subcutaneously in increasing dosage from 0.01 to 20 mg three times per week for 9 months. Stratification is performed for site and palliative chemotherapy. Main inclusion criteria are advanced pancreatic cancer and Eastern Cooperative Oncology Group performance status 0 to 2; main exclusion criteria are life expectancy less than 4 weeks and neuroendocrine tumour of the pancreas. Two ancillary studies on sub-sets of participants are nested in the trial: a biomarker study collecting blood samples and a cross-sectional qualitative study with semi-structured face-to-face interviews. DISCUSSION: To our knowledge, this is the first placebo-controlled randomised trial assessing the impact of mistletoe extract as a complement to standard treatment on overall survival and health-related quality of life in patients with advanced pancreatic cancer. The presented trial with its two nested ancillary studies exploring biomarkers and patient experiences is expected to give new insights into the treatment of advanced pancreatic cancer. TRIAL REGISTRATION: EU Clinical Trial Register, EudraCT Number 2014-004552-64 . Registered on 19 January 2016. ClinicalTrials.gov NCT02948309 . Registered on 28 October 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wode K, Hök Nordberg J, Kienle GS, et al. Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL). Trials. 2020. PMID: 32917288. doi:10.1186/s13063-020-04581-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。